Saturday, July 11, 2026

pharma · Leukemia, Lymphocytic, Acute, B-Cell · Prostate Cancer Indications

Shenzhen Second People's

Shenzhen Second People's trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
2
Drugs
4
Patents
0
Intelligence · Clinical Trials

Shenzhen Second People's clinical trials

Registry index of 2 ClinicalTrials.gov studies linked to Shenzhen Second People's programs — each row shows trial ID, program name, phase, status, and indication.

Shenzhen Second People's trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

2 updates

Latest clinical program signals indexed for Shenzhen Second People's.

  1. Immunomodulatory DC vaccines to target prostate cancer — Phase 2

    Clinical update
  2. CART19 cell and auto-HSCT — Phase 1

    Clinical update

Trial registry

2 studies